Source-grounded facts extracted from ALX ONCOLOGY HOLDINGS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ALX ONCOLOGY HOLDINGS INC shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2026-06-10 meeting.
“Proposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain 119,293,775 1,797 9,292”
ALX ONCOLOGY HOLDINGS INC shareholders approved Advisory Vote on the Compensation of the Company's Named Executive Officers at the 2026-06-10 meeting.
“Proposal 2: Advisory Vote on the Compensation of the Company’s Named Executive Officers For Against Abstain Broker Non-Votes 84,540,061 13,497,711 2,953,259 18,313,833”
ALX ONCOLOGY HOLDINGS INC shareholders approved Election of Two Class II Directors at the 2026-06-10 meeting.
“Proposal 1: Election of Two Class II Directors Name of Director For Withheld Broker Non-Votes Daniel Curran, M.D. 100,933,233 57,798 18,313,833 Rekha Hemrajani 82,732,430 18,258,601 18,313,833 Chris Takimoto, M.D., Ph.D., F.A.C.P. 100,946,696 44,335 18,313,833”
ALX ONCOLOGY HOLDINGS INC reported financial results for the first quarter ended March 31, 2026.
“On May 8, 2026, ALX Oncology Holdings Inc. (the “Company”), issued a press release announcing its financial results for the first quarter ended March 31, 2026.”
ALX ONCOLOGY HOLDINGS INC entered into Underwriting Agreement with Piper Sandler & Co., UBS Securities LLC and Wells Fargo Securities, LLC as representatives of the several underwriters valued at approximately $150 million (effective 2026-01-30).
“On January 30, 2026, ALX Oncology Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co., UBS Securities LLC and Wells Fargo Securities, LLC as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 76,979,112 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an offering price of $1.57 per share and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 18,574,120 shares of Common Stock at an offering price of $1.569 per Pre-Funded Warrant.”
ALX ONCOLOGY HOLDINGS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“April 23, 2025, ALX Oncology Holdings Inc. (the “Company”) received a written notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has not been in compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market set forth in Nasdaq Listing Rule 5450(a)(1) for a period of 30 consecutive business days (the “Notice”). The Notice has no immediate effect on the listing of the Company’s stock on the Nasdaq Global Select Market, subject to the Company’s compliance with the other lis”
ALX ONCOLOGY HOLDINGS INC announced a restructuring with charges of approximately $2.2 million affecting research and preclinical development (approximately 30% of the Company's employees).
“strategy. The reduction in workforce is expected to be substantially completed by the end of May 2025. The Company estimates that it will incur expenses of approximately $2.2 million for severance payments and employee benefits in connection with the reduction in force, primarily related to research and preclinical development, with the expenses expected to”
Jaume Pons departed as President and Chief Scientific Officer at ALX ONCOLOGY HOLDINGS INC.
“the Company’s President and Chief Scientific Officer position will be eliminated effective in April 2025”
Chris Takimoto was appointed as Director at ALX ONCOLOGY HOLDINGS INC.
“and Chris Takimoto, M.D., Ph.D., F.A.C.P., to serve as a Class III director of the Board”
Barbara Klencke was appointed as Director at ALX ONCOLOGY HOLDINGS INC.
“Effective January 18, 2025, the Board appointed Barbara Klencke, M.D. to serve as a Class II director of the Board”
Shelly Pinto resigned as Interim Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.
“Ms. Pinto resigned as the interim Chief Financial Officer effective as of the same date and will remain the Company’s Senior Vice President, Finance and Chief Accounting Officer and the principal accounting officer.”
Harish Shantharam was appointed as Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.
“Effective January 21, 2025, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) appointed Harish Shantharam to the office of Chief Financial Officer”
Alan Sandler resigned as member of the Board at ALX ONCOLOGY HOLDINGS INC.
“Effective on the same date, Dr. Sandler resigned as a member of the Board and all committees thereof.”
Peter Garcia resigned as Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.
“As previously disclosed, Peter Garcia resigned as Chief Financial Officer of the Company effective November 8, 2024, due to personal reasons.”
Alan Sandler was appointed as Chief Medical Officer at ALX ONCOLOGY HOLDINGS INC.
“On November 10, 2024, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) appointed Alan Sandler, M.D., age 68, to the office of Chief Medical Officer to fill a recently created vacancy.”
Shelly Pinto was appointed as Interim Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.
“On November 7, 2024, the Board of Directors (the “Board”) of the Company appointed Shelly Pinto, the Company’s Senior Vice President, Finance and Chief Accounting Officer, as the Company’s interim Chief Financial Officer, effective upon Mr. Garcia’s resignation.”
Peter Garcia resigned as Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.
“On November 5, 2024, Peter Garcia, Chief Financial Officer of the Company informed the Company of his resignation from his position effective November 8, 2024, due to personal reasons.”
Sophia Randolph resigned as Chief Medical Officer at ALX ONCOLOGY HOLDINGS INC.
“On September 30, 2024, Sophia Randolph, M.D., Ph.D., Chief Medical Officer of ALX Oncology Holdings Inc. (the “Company”) informed the Company of her resignation from her position effective October 11, 2024, to pursue other professional opportunities.”
Sophia Randolph resigned as Director at ALX ONCOLOGY HOLDINGS INC.
“In addition, on August 5, 2024, Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., resigned as members of the Company’s Board.”
Jaume Pons resigned as Director at ALX ONCOLOGY HOLDINGS INC.
“In addition, on August 5, 2024, Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., resigned as members of the Company’s Board.”
Alan Sandler was appointed as Director at ALX ONCOLOGY HOLDINGS INC.
“On August 5, 2024, the Board of Directors of ALX Oncology Holdings Inc. (the “Company”) appointed Alan Sandler, M.D. to serve as a Class III director of the Board of Directors of the Company (the “Board”) for a term expiring at the 2026 annual meeting of stockholders”
ALX ONCOLOGY HOLDINGS INC reported financial results for first quarter ended March 31, 2024.
“On May 9, 2024, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
Itziar Canamasas resigned as member of the Board of Directors at ALX ONCOLOGY HOLDINGS INC.
“On April 30, 2024, Itziar Canamasas, Ph.D., informed the Company of her resignation as a member of the Board and all committees thereof, effective immediately, due to her taking a new professional position that does not permit her to continue on as a director of the Company.”
Jack Nielsen resigned as member of the Board of Directors at ALX ONCOLOGY HOLDINGS INC.
“On April 28, 2024, Jack Nielsen informed ALX Oncology Holdings Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and all committees thereof, effective immediately, due to health reasons.”
ALX ONCOLOGY HOLDINGS INC reported the fourth quarter and full year ended December 31, 2023 results: net income GAAP net loss was $45.5 million for the fourth quarter ended December 31, 2023, or ($0.93) per basic and diluted share, EPS ($0.93) per basic and diluted share.
“On March 7, 2024, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.”
ALX ONCOLOGY HOLDINGS INC incurred term loan.
“The Third Amendment amends the Loan Agreement to, among other things, (i) extend the draw period for the Term A Loans from December 31, 2023 to June 30, 2024”
ALX ONCOLOGY HOLDINGS INC amended Third Amendment to Loan and Security Agreement with Oxford Finance LLC (effective 2023-12-22).
“On December 22, 2023, ALX Oncology Holdings Inc. (the “Company”) and its indirectly wholly-owned subsidiary, ALX Oncology Inc. (“Borrower”) entered into the Third Amendment to Loan and Security Agreement (the “Third Amendment”) by and among the Company as a guarantor, the Borrower, Oxford Finance LLC ("Oxford"), as collateral agent (“Agent”), and the lenders party thereto.”
ALX ONCOLOGY HOLDINGS INC reported financial results for the third quarter ended September 30, 2023.
“On November 13, 2023, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the third quarter ended September 30, 2023.”
ALX ONCOLOGY HOLDINGS INC entered into Underwriting Agreement with Piper Sandler & Co. and Cantor Fitzgerald & Co. valued at approximately $55.0 million (effective 2023-10-04).
“On October 4, 2023, ALX Oncology Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 7,370,690 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $6.38 per share (the “Underwritten Shares”) and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 1,250,000 shares of the Company’s common stock at a price to the public of $6.379 per Pre-Funded Warrant.”
ALX ONCOLOGY HOLDINGS INC reported preliminary financial results for the third quarter ended September 30, 2023.
“ALX Oncology Holdings Inc. (the “Company”), announced its preliminary estimate of cash, cash equivalents and short-term and long-term investments for the third quarter ended September 30, 2023. Based upon preliminary estimates and information available to the Company as of the date of this Form 8-K, it had approximately $196.5 million of cash, cash equivalents and short-term and long-term investments as of September 30, 2023.”
Jaume Pons changed role as President and Chief Scientific Officer at ALX ONCOLOGY HOLDINGS INC.
“Effective on the same date, Dr. Jaume Pons will no longer be the Company’s Chief Executive Officer and will serve as the Company’s Chief Scientific Officer while continuing to serve as President.”
Jason Lettmann was appointed as Chief Executive Officer at ALX ONCOLOGY HOLDINGS INC.
“On September 6, 2023, ALX Oncology Holdings Inc. (the “Company”) appointed Jason Lettmann, age 46 and a current member of the Company’s Board of Directors (the “Board”), as the Company’s Chief Executive Officer.”
ALX ONCOLOGY HOLDINGS INC reported financial results for the second quarter ended June 30, 2023.
“On August 10, 2023, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the second quarter ended June 30, 2023.”
ALX ONCOLOGY HOLDINGS INC: Amended and restated bylaws to enhance stockholder nomination and proposal procedures, revise stockholder meeting provisions, update director/committee/officer provisions, and conform to Delaware law (effective 2023-06-17).
“On June 16, 2023, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) approved the Company’s Amended and Restated Bylaws (the “Bylaws”) effective as of June 17, 2023.”
ALX ONCOLOGY HOLDINGS INC shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-06-16 meeting.
“Proposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain 38,518,146 8,803 3,009 The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
ALX ONCOLOGY HOLDINGS INC shareholders approved Advisory Vote on the Compensation of the Company’s Named Executive Officers at the 2023-06-16 meeting.
“Proposal 2: Advisory Vote on the Compensation of the Company’s Named Executive Officers For Against Abstain Broker Non-Votes 35,476,558 413,798 9,213 2,630,389 The stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the proxy statement for the Annual Meeting.”
ALX ONCOLOGY HOLDINGS INC shareholders approved Election of Three Class III Directors at the 2023-06-16 meeting.
“Proposal 1: Election of Three Class III Directors Name of Director For Withheld Broker Non-Votes Scott Garland 35,698,803 200,766 2,630,389 Rekha Hemrajani 31,953,951 3,945,618 2,630,389 Jaume Pons, Ph.D. 35,591,034 308,535 2,630,389 Each director nominee was duly elected to serve until the 2026 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”
ALX ONCOLOGY HOLDINGS INC reported financial results for first quarter ended March 31, 2023.
“On May 11, 2023, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the first quarter ended March 31, 2023.”
ALX ONCOLOGY HOLDINGS INC reported financial results for fourth quarter and full year ended December 31, 2022.
“ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2022.”
Scott Garland was appointed as Director at ALX ONCOLOGY HOLDINGS INC.
“Effective as of November 28, 2022, the Board of Directors of ALX Oncology Holdings Inc. (the “Company”) appointed Scott Garland to its Board of Directors and increased the size of its Board of Directors from seven to eight directors in connection with his appointment.”
ALX ONCOLOGY HOLDINGS INC reported financial results for the third quarter ended September 30, 2022.
“On November 8, 2022, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the third quarter ended September 30, 2022.”
ALX ONCOLOGY HOLDINGS INC entered into Loan and Security Agreement with Oxford Finance LLC and Lenders valued at up to $100 million aggregate principal amount, with $10 million initial funding (effective 2022-10-27).
“On October 27, 2022, ALX Oncology Holdings Inc., a Delaware corporation (the “Company”), entered into a loan and security agreement (the “Loan Agreement”) among Oxford Finance LLC, as collateral agent (“Agent”), and Oxford Finance LLC, Oxford Finance Credit Fund II LP, and Silicon Valley Bank, as the lenders from time to time party thereto (“Lenders”), ALX Oncology Inc., a Delaware corporation (“ALX”), Alexo Therapeutics International, an exempted company incorporated with limited liability under the laws of the Cayman Islands (“Alexo”), and Sirpant Therapeutics, an exempted company incorporated with limited liability under the laws of the Cayman Islands (“Sirpant” and, together with ALX and Alexo, the “Borrowers”), and the Company as a guarantor.”
Itziar Canamasas was appointed as Director at ALX ONCOLOGY HOLDINGS INC.
“Effective as of April 11, 2022, the Board of Directors of ALX Oncology Holdings Inc. (the “Company”) appointed Dr. Itziar Canamasas to its Board of Directors and increased the size of its Board of Directors from six to seven directors in connection with her appointment.”
Graham Walmsley resigned as director at ALX ONCOLOGY HOLDINGS INC.
“On August 26, 2021, Graham Walmsley, M.D., Ph.D., informed the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) that he would resign from the Board effective August 26, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.